Estimation of Percentage of US Patients Who Benefit From Genome-Driven Oncology

This cross-sectional study uses demographic data, FDA drug-approval information, drug labels, and other published sources to estimate the percentage of US patients with cancer who were eligible for and benefited from genome-driven oncology from January 2006 through January 2018.

https://ift.tt/2Hxi56u